Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Prostatic Neoplasms 2Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Recurrence 1Neoplasm, Residual 1Multiple Myeloma 1Melanoma 1Esophageal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Hepatocellular 1Adenocarcinoma of Lung 1Adenocarcinoma 1

Interventions

Trastuzumab 597Paclitaxel 562Cyclophosphamide 545Docetaxel 479Capecitabine 388Letrozole 350Fulvestrant 311Doxorubicin 285Carboplatin 277Tamoxifen 257Anastrozole 219exemestane 211Epirubicin 210Radiotherapy 197Bevacizumab 189pertuzumab 177Gemcitabine 163Vinorelbine 162pembrolizumab 161Lapatinib 161palbociclib 152Exercise 132Fluorouracil 118Albumin-Bound Paclitaxel 116eribulin 108Magnetic Resonance Spectroscopy 108130-nm albumin-bound paclitaxel 107Everolimus 103Taxes 96Cisplatin 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Breast Neoplasms × tetrathiomolybdate × Clear all
NCT00195091 2025-05-16

Phase II Study of Tetrathiomolybdate (TM) in Patients With Breast Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Terminated
16 enrolled 5 charts
Breast

Breast Neoplasms

NCT00674557 2013-07-10

Exemestane With or Without ATN-224 in Treating Postmenopausal Women With Recurrent or Advanced Breast Cancer

National Cancer Institute (NCI)

Phase 2 Terminated
111 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡